A targeted approach to the proliferation, fibrosis, and inflammation associated with Pulmonary Arterial Hypertension

A targeted approach to the proliferation, fibrosis, and inflammation associated with Pulmonary Arterial Hypertension

Targeting the underlying mechanisms of Pulmonary Arterial Hypertension

Now Enrolling: The PROSERA Phase 3 study of seralutinib in adults with Pulmonary Arterial Hypertension (PAH).

PROSERA clinical trial: NCT05934526

Learn more about the study